Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Leukemia, Myeloid, Acute 13Myelodysplastic Syndromes 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Hodgkin Disease 7Leukemia, Biphenotypic, Acute 5Burkitt Lymphoma 5Lymphoma, Non-Hodgkin 4Hematologic Neoplasms 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Neuroblastoma 3Neoplasms 3Leukemia, Myelomonocytic, Chronic 3Rhabdomyosarcoma 2Myeloproliferative Disorders 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia 2Teratoma 1Solid Tumors 1Sarcoma 1Recurrence 1Myelodysplastic-Myeloproliferative Diseases 1Multi-centric Castleman's Disease 1Malignant mesenchymal tumor 1Macular dystrophy, corneal type 1 1Lymphoproliferative Disorders 1Lymphoma, T-Cell 1

Interventions

Carboplatin 6Radiotherapy 5Radiation 4Nivolumab 4Magnetic Resonance Spectroscopy 4Specimen Handling 3Pemetrexed 3Biopsy 3Bevacizumab 3capmatinib 2Radiotherapy, Conformal 2Platinum 2Paclitaxel 2Ipilimumab 2Immunoglobulin G 2Disulfides 2Cisplatin 2CTLA-4 Antigen 21,2-diaminocyclohexaneplatinum II citrate 2veliparib 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1osimertinib 1methoxyamine 1lazertinib 1fludarabine phosphate 1durvalumab 1defactinib 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma of Lung × Filgrastim × 90 days × Clear all
NCT00334815 2026-05-26

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Active not recruiting
29 enrolled 10 charts
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar

Data powered by HemOnc (CC BY 4.0) Colophon âš¡